Skip to main content
Clinical Trials/NCT06588244
NCT06588244
Recruiting
Not Applicable

Ischemia in Patients with Non- Obstructive Disease (INOCA) - a Local Prospective Registry (INOCA-Naples)

Federico II University1 site in 1 country250 target enrollmentSeptember 19, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemia, Myocardial
Sponsor
Federico II University
Enrollment
250
Locations
1
Primary Endpoint
MACE
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The present study has the following objectives:

  1. To investigate the prevalence of INOCA in patients referring for a clinically indicated coronary angiography (CA) c/o Division of Cardiology - Federico II University Hospital;
  2. To stratify in INOCA endotypes patients according to the presence or absence of alternative (i.e. non obstructive CAD) causes of myocardial ischemia detected during CA clinically indicated through physiology tests;
  3. to implement a stratified therapy in these patients considering the different INOCA endotypes and evaluate the impact on angina class and quality of life as well as cardiac hospitalization and coronary revascularization during 5 year follow up

Detailed Description

Eligible patients with angina and/or positive stress test undergoing clinical indicated CA detecting non-obstructive CAD will be studied as follows: * Functional evaluation by fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), Resting Full-Cycle Ratio (RFR) of any stenosis that is angio- graphically considered \> 50%; * In case of stenosis \<50% or \>50% but with negative functional evaluation (FFR \>0.80 and iFR/RFR \>0.90), coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed. IMR and CFR will be evaluated, using an intracoro- nary wire; * In case of CFR\>2.0 and IMR\<25, acetylcholine test will be performed. Intracoronary acetylcholine (ACh) will be administrated to detect epicardial (fo- cal or diffuse) or microvascular spasm.

Registry
clinicaltrials.gov
Start Date
September 19, 2024
End Date
September 1, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Luigi Di Serafino

Principal Investigator, Clinical Professor

Federico II University

Eligibility Criteria

Inclusion Criteria

  • Clinical presentation of chronic ischemic heart dis- ease (IHD), requiring coronary angiography for the diagnosis;
  • Absence of obstructive coronary artery disease (CAD) at coronary angiography;
  • Age \> 18 years.
  • Ability to provide a valid informed consent to the study procedure at the time of baseline evaluation;

Exclusion Criteria

  • Clinical presentation of acute coronary syndrome (ACS) or cardiogenic shock;
  • Presence of obstructive CAD with at least 1 significant coronary artery stenosis, defined as diameterstenosis \>50% and FFR ≤0.80 (or iFR/RFR ≤0.89);
  • Previous coronary artery bypass grafting (CABG);
  • Left ventricular systolic dysfunction, defined as ejection fraction (EF) \<40%;
  • Severe valvular heart disease;
  • Pregnant or breastfeeding women
  • Known hypersensitivity or contraindication to any of the drugs used for coronary physiology testing (adenosine, nitrates, acetylcholine)
  • Inability or unwillingness to provide a valid in- formed consent to the study procedure at the time of baseline evaluation.

Outcomes

Primary Outcomes

MACE

Time Frame: 12 and 60 months

Occurrence of Cardiovascular death, Myocardial infarction, Coronary revascularization

Degree of Angina

Time Frame: 12 and 60 months

The degree of angina will be assessed using The Seattle Angina Questionnaire - 7 (SAQ-7) contains 7 questions used to measure health status in patients with coronary artery disease (CAD). The score is generated for each domain and it is scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status.

QoL

Time Frame: 12 and 60 months

Quality of life will be assessed using the 5-level EuroQoL 5-dimensions Questionnaire (EQ-5D-5L). The EQ-5D-5L descriptive system comprises the same five dimensions as the EQ-5D-3L (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN/DISCOMFORT and ANXIETY / DEPRESSION), but each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health state by checking the box next to the most appropriate response level for each of the five dimensions. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. An EQ-5D health state is deemed to be 'better' than another if it is better on at least one dimension and is no worse in any other dimension. An EQ-5D health state is deemed to be 'worse' than another if it is worse in at least one dimension and is no better in any other dimension.

Study Sites (1)

Loading locations...

Similar Trials